IP Library › Granted Patent US 10,526,321
Granted Patent B2
US 10,526,321 · App. 15/979,770 · Granted Jan 7, 2020

Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Inventors: Stephen T. Wrobleski (Flemington, NJ); Shuqun Lin (Newtown, PA)
Assignee: Bristol-Myers Squibb Company
C07D417/14C07B59/002C07D237/24C07D401/12C07D401/14C07D403/12C07D403/14C07D413/12C07D413/14C07D417/12C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,526,321
App. No.
15/979,770
Granted
Jan 7, 2020
Kind
B2
Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Claims (1)

1. A compound of the formula

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2021
From: LIN, SHUQUN
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 056025/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2021
From: WROBLESKI, STEPHEN T.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 056025/0696 →
Continuity (4)
Continuation 15289437 · Oct 10, 2016
Continuation 14441183
Provisional Application 61723840 · Nov 8, 2012
Related Publication 20180265504A1 · Sep 20, 2018
Cited By (2)
US 12,600,721 US 12,668,594